AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

May 11, 2021 | Last Trade: US$4.03 0.23 5.92

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time.

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. To learn more, please visit us at www.abcellera.com.

Source: AbCellera Biologics Inc.

Stock Quote

Last Trade:	US$4.03
Daily Change:	0.23 5.92
Daily Volume:	7,273,667
Market Cap:	US$1.190B

May 30, 2025 AbCellera Biologics Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 May 14, 2025 AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause May 12, 2025 AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit May 09, 2025 AbCellera Biologics Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting May 08, 2025 AbCellera Reports Q1 2025 Business Results LOAD MORE NEWS

Featured Stock

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE